The earnings transcript for Johnson & Johnson's Q1 2022 results indicates several key points that could influence the stock price in the short term:

## Positive Indicators
- The company reported a 5% total sales growth to $23.4 billion, with operational growth of 7.7% and adjusted operational growth of 7.9%, demonstrating strong performance across the enterprise despite macro-economic headwinds[1][2][5].
- Adjusted earnings per share increased by 3.1% to $2.67, beating expectations[1][2][5].
- Strong performance in the Pharmaceutical segment, driven by products like DARZALEX, TREMFYA, and ERLEADA, with above-market adjusted operational sales growth[1][2].
- MedTech sales grew by 8.5%, driven by market recovery, commercial strategies, and new product launches[1][2].

## Challenges
- The company faced challenges due to the COVID-19 pandemic, including supply constraints in Consumer Health and delays in surgical procedures, though these are expected to improve in the second half of the year[1][2].
- COVID-19 vaccine sales were below expectations, leading to the suspension of vaccine sales guidance[1][2].
- Inflationary pressures and commodity scarcity impacted margins, though the company is implementing cost-saving measures[1][2].

## Guidance and Outlook
- The company maintained its full-year guidance for adjusted operational earnings per share and base business operational sales, despite suspending COVID-19 vaccine sales guidance[1][2].
- Expectations for a stronger second half in both Consumer Health and MedTech segments[1][2].

Given these points, the overall tone of the earnings call is positive, highlighting strong operational performance and growth in key segments, despite some short-term challenges. However, the suspension of COVID-19 vaccine sales guidance and ongoing macroeconomic headwinds might introduce some caution.

### Conclusion
The stock is likely to see a positive impact in the short term due to the strong operational growth, solid financial performance, and maintained guidance for the full year.

**Rating: 1**